Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 13/20 | 0.51 |
| ▸ | TDO2 | P48775 | 13/20 | 0.51 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.42 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.39 |
| ▸ | NOS1 | P29475 | 1/20 | 0.39 |
| ▸ | METAP2 | P50579 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17441894 | 0.83 | TDO2 (0.47) | IDO1TDO2DYRK1ACYP2C9 | |
| SCHEMBL2008097 | 0.81 | IDO1 (0.56) | IDO1TDO2DYRK1ANOS1METAP2 | |
| SCHEMBL29990549 | 0.81 | IDO1 (0.56) | IDO1TDO2DYRK1ANOS1METAP2 | |
| SCHEMBL17440928 | 0.77 | MAOB (0.45) | IDO1TDO2METAP2 | |
| SCHEMBL25048664 | 0.76 | TSHR (0.46) | IDO1TDO2CYP2C9 | |
| SCHEMBL29835228 | 0.76 | TSHR (0.46) | IDO1TDO2CYP2C9 | |
| SCHEMBL29003303 | 0.75 | IDO1 (0.49) | IDO1TDO2DYRK1ANOS1METAP2 | |
| SCHEMBL27871144 | 0.75 | TDO2 (0.49) | IDO1TDO2DYRK1ANOS1METAP2 | |
| SCHEMBL28616957 | 0.74 | FGFR1 (0.44) | IDO1TDO2FGFR2FGFR1NOS1 | |
| SCHEMBL19249080 | 0.74 | IDO1 (0.51) | IDO1TDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067610-A1 | INHIBITORS OF NLRP3 INFLAMMASOME | BioAge Labs, Inc. | 2024-02-29 | — | — | US | disclosed |
| US-20240067610-A1 | INHIBITORS OF NLRP3 INFLAMMASOME | BioAge Labs, Inc. | 2024-02-29 | — | — | US | disclosed |
| US-20230365507-A1 | INHIBITORS OF NLRP3 INFLAMMASOME | BioAge Labs, Inc. | 2023-11-16 | — | — | US | disclosed |
| US-11708334-B2 | Inhibitors of NLRP3 inflammasome | BioAge Labs, Inc. (US) | 2023-07-25 | — | — | US | disclosed |
| US-11708334-B2 | Inhibitors of NLRP3 inflammasome | BioAge Labs, Inc. (US) | 2023-07-25 | — | — | US | disclosed |
| US-11702391-B2 | Inhibitors of NLRP3 inflammasome | BioAge Labs, Inc. (US) | 2023-07-18 | — | — | US | disclosed |
| US-11702391-B2 | Inhibitors of NLRP3 inflammasome | BioAge Labs, Inc. (US) | 2023-07-18 | — | — | US | disclosed |
| US-11427561-B2 | IRAK4 inhibiting agents | BIOGEN MA INC. (US) | 2022-08-30 | — | — | US | disclosed |
| EP-3405465-B1 | IRAK4 INHIBITING AGENTS | BIOGEN MA INC (US) | 2021-10-13 | — | — | EP | disclosed |
| US-20210188809-A1 | IRAK4 INHIBITING AGENTS | BIOGEN MA INC. | 2021-06-24 | — | — | US | disclosed |
| US-20190248787-A1 | IRAK4 INHIBITING AGENTS | BIOGEN MA INC. | 2019-08-15 | — | — | US | disclosed |
| US-20190248787-A1 | IRAK4 INHIBITING AGENTS | BIOGEN MA INC. | 2019-08-15 | — | — | US | disclosed |
| US-10246456-B2 | IRAK4 inhibiting agents | BIOGEN MA INC. (US) | 2019-04-02 | — | — | US | disclosed |
| US-10246456-B2 | IRAK4 inhibiting agents | BIOGEN MA INC. (US) | 2019-04-02 | — | — | US | disclosed |
| EP-3405465-A1 | IRAK4 INHIBITING AGENTS | Biogen MA Inc. (US) | 2018-11-28 | — | — | EP | disclosed |
| WO-2017127430-A1 | IRAK4 INHIBITING AGENTS | BIOGEN MA INC. (US) | 2017-07-27 | — | — | WO | disclosed |
| US-20170204093-A1 | IRAK4 INHIBITING AGENTS | BIOGEN MA INC. | 2017-07-20 | — | — | US | disclosed |
| US-20170204093-A1 | IRAK4 INHIBITING AGENTS | BIOGEN MA INC. | 2017-07-20 | — | — | US | disclosed |
| WO-2016011390-A1 | IRAK4 INHIBITING AGENTS | BIOGEN MA INC. (US) | 2016-01-21 | — | — | WO | disclosed |
| WO-2016011390-A1 | IRAK4 INHIBITING AGENTS | BIOGEN MA INC. (US) | 2016-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11708334-B2 | Inhibitors of NLRP3 inflammasome | NLRP3, NLRP1, PYCARD | IDO1 1641/4885TDO2 4023/4885DYRK1A 4787/4885 |
| US-10246456-B2 | IRAK4 inhibiting agents | IRAK4, IRAK1, IRAK2 | IDO1 2532/4885TDO2 4666/4885DYRK1A 2347/4885 |
| US-11427561-B2 | IRAK4 inhibiting agents | IRAK4, IRAK1, IRAK2 | IDO1 2204/4885TDO2 4729/4885DYRK1A 2226/4885 |
| US-20210188809-A1 | IRAK4 INHIBITING AGENTS | IRAK4, IRAK1, IRAK2 | IDO1 2204/4885TDO2 4729/4885DYRK1A 2226/4885 |
| US-20240067610-A1 | INHIBITORS OF NLRP3 INFLAMMASOME | NLRP3, PYCARD, CASP1 | IDO1 1369/4885TDO2 3870/4885DYRK1A 4675/4885 |
| US-20170204093-A1 | IRAK4 INHIBITING AGENTS | IRAK4, IRAK1, IRAK2 | IDO1 2532/4885TDO2 4666/4885DYRK1A 2347/4885 |
| US-11702391-B2 | Inhibitors of NLRP3 inflammasome | NLRP3, CASP1, PYCARD | IDO1 1395/4885TDO2 3761/4885DYRK1A 4830/4885 |
| US-20190248787-A1 | IRAK4 INHIBITING AGENTS | IRAK4, IRAK1, IRAK2 | IDO1 2524/4885TDO2 4645/4885DYRK1A 2105/4885 |
| US-20230365507-A1 | INHIBITORS OF NLRP3 INFLAMMASOME | NLRP3, PYCARD, CASP1 | IDO1 1369/4885TDO2 3870/4885DYRK1A 4675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.